https://www.avient.com/sites/default/files/resources/Terms%2520and%2520Conditions%2520of%2520Sale%2520for%2520Hungary.pdf
PAYMENTS
Unless otherwise directed or agreed to by Seller, all
invoices are payable thirty (30) days after the date of
invoice.
FIZETÈSEK
Amennyiben más megállapodás vagy rendelkezés
nincs Eladóval, minden számlát a kiállítástól számított
harminc (30) napon belül kell megfizetni.
PRICE AND TERMS ADJUSTMENT
Seller may change any price, freight term and/or term
of payment by giving Buyer thirty (30) days prior
written notice.
https://www.avient.com/sites/default/files/2020-08/avient-investor-presentation-jefferies-industrials-conference.pdf
Avient Corporation 1
J E F F E R I E S V I R T U A L
I N D U S T R I A L S
C O N F E R E N C E
A U G U S T 2 0 2 0
Avient Corporation 2
FORWARD LOOKING STATEMENTS
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Avient Corporation 3
U S E O F
N O N - G A A P
M E A S U R E S
•
•
•
Avient Corporation 4
U P D A T E O N T H E
C O V I D - 1 9 P A N D E M I C
•
•
•
•
Avient Corporation 5
2019 Transportation Consumer
Discretionary
Healthcare Packaging All Other
Industries
Cost
Containment
FX 2020
$64.3 18%
18%
9%
6%
16% 2% $46.9
20%
•
•
•
•
•
•
S E C O N D Q U A R T E R 2 0 2 0 I N R E V I E W
Consumer
Discretionary
Avient Corporation 6
CLARIANT MASTERBATCH
STRATEGIC RATIONALE
Avient Corporation 7
F I T W I T H F O U R P I L L A R S T R A T E G Y
Specialization
•
•
•
Globalization
•
•
Operational
Excellence
•
•
•
Commercial
Excellence
•
•
People
Avient Corporation 8
5%
2006 2019E PF*
4%
12%
10%
18%
8%
20%
2006 2019E PF*
Healthcare
Consumer
Packaging
38%
* 2019E Pro Forma for PP&S Divestiture and Clariant Masterbatch business
Percentage of Total Revenue
E N D M A R K E T T R A N S F O R M A T I O N
Building & Construction High Growth End Markets
50%
22%
Avient Corporation 9
Wire & Cable
11%
Industrial
10%
Electrical &
Electronic
7%
Healthcare
4%
Packaging
8%
Consumer
10%
Transportation
12%
Building &
Construction
38%
Healthcare
12%
Packaging
20%
Consumer
18%Transportation
12%
Building &
Constrution
5%
Wire & Cable
9%
Industrial
11%
Electrial &
Electronic
4%
Appliance
2%
Textiles
7%
2006 Pro Forma(1)
Net Sales by End Market
E N D M A R K E T T R A N S F O R M A T I O N
Avient Corporation 10
U N I F I E D F O C U S O N S U S T A I N A B I L I T Y
2006 - 2013
2013 – 2019
P E O P L E
P R O D U C T S P L A N E T
P E R F O R M A N C E
••
••
••
Avient Corporation 11
O V E R 8 5 % O F A D J U S T E D E B I T D A F R O M S P E C I A L T Y
46%
66%
0%
20%
40%
60%
80%
100%
2005 2010 2015 Pro Forma
%
o
f
A
d
ju
s
t
e
d
E
B
IT
D
A
(
1
)
JVs Performance Products & Solutions Distribution Specialty
7%
87%
(2)
Avient Corporation 12
T H E N E W A V I E N T : A S P E C I A L T Y G R O W T H C O M P A N Y
Transaction expected to add $0.85 to pro forma adjusted EPS
Avient Corporation 13
SUSTAINABILITY AT AVIENT
P E O P L E , P R O D U C T S , P L A N E T , P E R F O R M A N C E
Avient Corporation 13
Avient Corporation 14
V I S I O N
To be the world’s
premier provider of
specialized polymer
materials, services and
solutions
C O R E
V A L U E S
P E R S O N A L
V A L U E S
Honesty IntegrityRespect
Operational
Excellence
Commercial
Excellence
Specialization
Globalization
Collaboration ExcellenceInnovation
To be the world’s
premier provider of
specialized polymer
materials, services
and sustainable
solutions
Avient Corporation 15
1.3
1.1 1.1
0.85
0.65
0.57
0.54
0.97
0.84
0.74 0.74
0.69
0.51
0.56
0.14
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
YTD
S A F E T Y F I R S T
Injuries per 100 Workers
Spartech
Acquisition
Avient Corporation 16
G R E A T P L A C E T O W O R K
Avient Corporation 17
C O M M O D I T Y T O S P E C I A L T Y T R A N S F O R M A T I O N
•
•
•
•
•
•
•
•
•
•
•
•
2006 - 2013 2013 – 20192000-2005 2006 - 2013
•
•
2020 and
Beyond
Avient Corporation 18
A V I E N T
2 0 1 9 R E V E N U E | $ 2 . 9 B I L L I O N
Segment End Market Geography
Healthcare
15%
Industrial
14%
Consumer
14%
Packaging
13%
Transportation
13%
Wire & Cable
11%
Building &
Construction
6%
Electrical &
Electronics
6%
Textiles
5%
Appliance
3%
Color
Additives
& Inks
34%
Distribution
41%
Specialty
Engineered
Materials
25%
United States
54%
Europe
19%
Asia
11%
Latin
America
11%
Canada
5%
Avient Corporation 19
Operating Income
% of Sales
2006 2019
Color, Additives &
Inks
1.7% 14.7%
Specialty Engineered
Materials
1.1% 11.6%
Distribution 2.6% 6.3%
2009 2010 2011 2012 2013 2014 2015 2016* 2017* 2018
$2.43
P R O O F O F P E R F O R M A N C E
C O N S E C U T I V E
Y E A R S
1 0
$0.13
$0.68
$0.82
$1.00
$1.31
$1.80
$1.96
$2.06
$2.21
A D J U S T E D E P S E X P A N S I O N
2018 2019
$1.69
$1.51
Avient Corporation 20
531
710
1,032
130
164
207
504
663
871
2014 2018 Pro Forma
R&D / Technical Marketing Sales
+ 34%
+ 26%
+ 32%
E X P A N S I O N O F C O M M E R C I A L R E S O U R C E S D R I V I N G G R O W T H
Revenue in Billions
Total
+ 10%
Organic
+ 7%+ 45%
+ 26%
+ 31%
$4.0
$3.2
(2) (1) (1)
$2.9 $2.9
$3.5
2015 2016 2017 2018 Pro
Forma
Total
+ 9%
Organic
+ 5%
Pro Forma(2)
Avient Corporation 21
P R I O R A C Q U I S I T I O N S H I S T O R Y
Commercial
Resources(1)
Operating
Income
($ in millions)
Operating
Margins
256
350
At Acquisition 2019
$36
$100
At Acquisition 2019
9%
19%
At Acquisition 2019
Established Acquisitions
(> 7 years)
+ 37% + 176% + 1000 bps
Avient Corporation 22
A L I G N I N G W I T H T R E N D S F O R G R O W T H
T R A N S P O R T A T I O N P A C K A G I N G H E A L T H C A R E C O N S U M E R
Facilitate
alternative
energy
solutions
Light-
weighting
Reduce
packaging
materials
Improve
recyclability
Reduce
spread of
infection
Avient Corporation 23
I N N O V A T I O N
Customization
55%
M&A
30%
Innovation
Pipeline
15%
Innovation comes from Research & Development Spend
Vitality Index
12%
37%
2006 2019
$20
$51
2006 2019
Avient Corporation 24
R E V E N U E F R O M S U S T A I N A B L E S O L U T I O N S
$275M
$325M
$355M
$410M 14% Total Annual Growth
9% Organic Annual Growth
Avient Corporation 25
SEGMENT
HIGHLIGHTS
I N N O V A T I N G W I T H A V I E N T
Avient Corporation 25
Avient Corporation 26
C O L O R , A D D I T I V E S & I N K S
E N D M A R K E T S & S O L U T I O N S
Solid
Colorants
Performance
Additives
Screen
Printing Inks
Liquid
Colorants
Packaging
31%
Industrial
14%
Textiles
13%
Wire & Cable
10%
Building & Construction
9%
Consumer
8%
Transportation
7%
Healthcare
5%
Appliances
2%
Electrical & Electronics
1%
Avient Corporation 26
Avient Corporation 27
Operating Income & MarginRevenue by Region
C O L O R , A D D I T I V E S & I N K S
2 0 1 9 R E V E N U E | O V E R $ 1 B I L L I O N
Europe
34%
United
States
44%
Asia
15%
Canada
1%
Mexico
3%
South
America
3%
$4
$25
$104
$147
2005 2009 2013 2019
0.9%
5.5%
12.2%
14.7%
Avient Corporation 27
Avient Corporation 28
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
E N D M A R K E T S & S O L U T I O N S
Engineered
Formulations
Advanced
Composites
Thermoplastic
Elastomers
Wire & Cable*
28%
Consumer
19%
Electrical & Electronics
12%
Healthcare
9%
Industrial
8%
Packaging
6%
Appliance
2%
Building &
Construction
2%
Transportation
14%
Avient Corporation 28
Avient Corporation 29
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
Revenue by Region Operating Income & Margin
2 0 1 9 R E V E N U E | $ 7 5 0 M I L L I O N
Europe
27%
United
States
54%
Asia
17%
Canada
2%
$21
$57
$87
2005 2009 2013 2019
0.1%
5.1%
9.3%
11.6%
Avient Corporation 29
Avient Corporation 30
D I S T R I B U T I O N
E N D M A R K E T S & S U P P L I E R S
Healthcare
28%
Industrial
19%
Transportation
18%
Consumer
17%
Appliance
6%
Electrical &
Electronics
5%
Building &
Construction
4%
Packaging
2%
Wire & Cable
1%
Operating Income & Margin2019 Revenue | $1.2 Billion
$25
$63
$75
2005 2009 2013 2019
$20
2.9%
4.0%
5.9%
6.3%
Avient Corporation 30
http://www.avient.com/Pages/VariationRoot.aspx
Avient Corporation 31
O V E R V I E W O F R A W M A T E R I A L P U R C H A S E S
Avient Corporation 31
Avient Corporation 32
Avient Corporation 33
Adjusted EPS attributable to PolyOne common shareholders is calculated as follows:
2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018***
Q1
2019*** 2019
Q1
2020
Net income from continuing operations attributable to PolyOne
common shareholders
Joint venture equity earnings, after tax
Special items, before tax
(1)
Special items, tax adjustments
(1)
Adjusted net income from continuing operations attributable to
PolyOne common shareholders
$ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1
(19.0) (14.7) (3.7) — — — — — — — — — — —
(48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6
(27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0)
$ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7
Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7
Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48
* Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation.
** Pro forma for sale of Designed Structures and Solutions segment (DSS).
*** Pro forma for sale of Performance Products and Solutions segment (PP&S).
Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering and May 2020 Debt Offering
Three Months Ended
June 30, 2020
Net income from continuing operations attributable to Avient common shareholders $ 23.0
Special items, after tax(1) 2.6
After tax interest expense, net arising from equity offering and debt offering proceeds 4.1
Adjusted net income excluding special items and impact of interest expense, net arising from equity offering and debt offering proceeds $ 29.7
Diluted weighted-average shares used to compute earnings per common share 91.8
Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (15.3)
Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 76.5
Adjusted EPS excluding special items and impact of equity offering and debt offering $ 0.39
(1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures,
including adjustments related to contingent consideration; employee separation costs resulting from personnel reduction programs, plant realignment costs, executive separation agreements; asset impairments; settlement
gains or losses and mark-to-market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance
recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, joint ventures and equity investments; gains and losses on facility or property sales or
disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non- recurring items; and the effect
of changes in accounting principles or other such laws or provisions affecting reported results.
https://www.avient.com/sites/default/files/resources/PDI_Healthcare_Brochure_2011_0.pdf
PDI scientists have
on average 30 years each in the industry and are ready to take on any challenge.
PDI scientists have
on average 30 years each in the industry and are ready to take on any challenge.
https://www.avient.com/sites/default/files/2022-02/MEVOPUR Bio-based Solutions Application Bulletin_JP.pdf
1)30日以上、人体組織または体液に暴露すること。
3)生殖器用インプラントまたは避妊具、または
(4)人間の生命を支え、維持する永久的(30日以上)移植された医療機器の重要な構成要素。
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-and-additives-for-ivd-devices-application-bulletin-cn.pdf
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2022-03/MEVOPUR Chemical Foaming Agents Application Bulletin_JP.pdf
1)30日以上、人体組織または体液に暴露すること。
3)生殖器用インプラントまたは避妊具、または
(4)人間の生命を支え、維持する永久的(30日以上)移植された医療機器の重要な構成要素。
https://www.avient.com/sites/default/files/2022-03/Trilliant HC Electrically Conductive Formulations for Pipette Tips Application Bulletin.pdf
KEY PERFORMANCE PROPERTIES1
PHYSICAL NOMINAL VALUE UNIT TEST METHOD
Density/Specific Gravity 1.00 ASTM D792
Melt Mass-Flow Rate (MFR) (230°C/2.16kg) 20 g/10 min ASTM D1238
MECHANICAL
Tensile Strength 15.0 MPa ASTM D638
Flexural Modulus 1400 MPa ASTM D790
Flexural Strength 35.0 MPa ASTM D790
IMPACT
Notched Izod Impact (Injection Molded) 150 J/m ASTM D256
ELECTRICAL
Surface Resistivity < 100000 ohms/sq ASTM D257
PROCESSING INFORMATION
INJECTION NOMINAL VALUE UNIT
Drying Temperature 80 to 90 °C
Drying Time 4.0 to 6.0 hr
Processing (Melt) Temperature 220 to 250 °C
Mold Temperature 30 to 80 °C
Trilliant™ HC Electrically Conductive Formulations
for Precision Performance Pipette Tips
A critical design consideration for pipette tips is
the accurate measurement of finite amounts of
liquid.
https://www.avient.com/sites/default/files/2021-01/sem-base-station-antenna-application-bulletin.pdf
Better Performance-to-Cost Ratios – Traditionally
used materials can cost 30–40% more than a
thermoplastic solution at only slightly better
performance.
https://www.avient.com/sites/default/files/2021-04/gravi-tech-pipe-system-valve-case-study.pdf
However, most brass flapper valves open only
25–30 percent, preventing the pig from passing through.
https://www.avient.com/sites/default/files/2020-08/colormatrix-optica-toner-dispersions-tech-bulletin-a4.pdf
The maximum particle size
in both products is 30 microns.